BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 172 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $37,701 | +1.2% | 5,325 | +0.6% | 0.00% | – |
| Q2 2023 | $37,249 | +232706.2% | 5,291 | +175.6% | 0.00% | – |
| Q1 2023 | $16 | -78.1% | 1,920 | -69.8% | 0.00% | -100.0% |
| Q4 2022 | $73 | -99.9% | 6,350 | +0.2% | 0.00% | 0.0% |
| Q3 2022 | $85,000 | +28.8% | 6,339 | +2.1% | 0.00% | 0.0% |
| Q2 2022 | $66,000 | -34.7% | 6,210 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $101,000 | -5.6% | 6,210 | -10.5% | 0.00% | 0.0% |
| Q4 2021 | $107,000 | -35.2% | 6,940 | -39.7% | 0.00% | 0.0% |
| Q3 2021 | $165,000 | -9.3% | 11,500 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $182,000 | +50.4% | 11,500 | -3.6% | 0.00% | 0.0% |
| Q1 2021 | $121,000 | +450.0% | 11,925 | +307.7% | 0.00% | – |
| Q4 2020 | $22,000 | +214.3% | 2,925 | +41.0% | 0.00% | – |
| Q3 2020 | $7,000 | -30.0% | 2,075 | 0.0% | 0.00% | – |
| Q2 2020 | $10,000 | +150.0% | 2,075 | +5.3% | 0.00% | – |
| Q1 2020 | $4,000 | -50.0% | 1,970 | +97.0% | 0.00% | – |
| Q1 2017 | $8,000 | +14.3% | 1,000 | -61.5% | 0.00% | – |
| Q1 2016 | $7,000 | – | 2,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 7,637,700 | $77,675,000 | 7.44% |
| Burrage Capital Management LLC | 864,916 | $8,796,000 | 7.13% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,367,670 | $24,079,000 | 3.61% |
| HealthCor Management, L.P. | 4,886,440 | $49,695,000 | 1.76% |
| Ghost Tree Capital, LLC | 500,000 | $5,085,000 | 1.20% |
| Integral Health Asset Management, LLC | 400,000 | $4,068,000 | 1.16% |
| Lisanti Capital Growth, LLC | 472,520 | $4,806,000 | 0.62% |
| Parkman Healthcare Partners LLC | 244,680 | $2,488,000 | 0.58% |
| Baker Brothers Advisors | 12,710,818 | $129,269,000 | 0.56% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,605,380 | $26,497,000 | 0.56% |